Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04985812 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

A Phase 1 study of Rheumatoid Arthritis, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
11
Study locations

NCT04985812: Completed Phase 1 study of Rheumatoid Arthritis, sponsored by Janssen Research & Development.

NCT04985812 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Janssen Research & Development. The registered enrollment target is 44 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04985812, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).

Primary Outcome

An adverse event (AEs) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are AEs with onset during the treatment phase or that are a consequence of a pre-existing condition that has worsened since baseline.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG JNJ-67484703

Study Locations (11)

Other

  • Arensia Exploratory Medicine - Tbilisi
  • Budai Irgalmasrendi Korhaz - Budapest
  • Clinexpert Kft - Gyöngyös
  • CRU Hungary Kft. - Kistarcsa
  • Arensia Exploratory Medicine - Chisinau
  • Hosp Univ A Coruna - A Coruña
  • Hosp. Clinico San Carlos - Madrid
  • Hosp. Univ. 12 de Octubre - Madrid
  • ARENSIA Exploratory Medicine Unit - Kiev

Alabama

  • Pinnacle Research Group, LLC - Anniston

Illinois

  • GCSP/CIS Orland Park - Orland Park

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2021-10-18
Est. Completion 2023-05-18
Phase Phase 1
Janssen Research & Development

593 total trials

What the finished NCT04985812 record still lists

NCT04985812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04985812 lists 11 locations in 3 states (Other, Alabama, Illinois).

Frequently Asked Questions

What is clinical trial NCT04985812 about?

NCT04985812 is a clinical study titled "A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis". The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).

What is the current status of trial NCT04985812?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2021-10-18. Estimated completion is 2023-05-18.

What conditions does trial NCT04985812 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT04985812?

The interventions under investigation include: Placebo (DRUG), JNJ-67484703 (DRUG).

Who is sponsoring clinical trial NCT04985812?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04985812 being conducted?

This trial has 11 study locations across Alabama, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04985812's enrollment target sits among peer trials

44 146th of 197 higher than 52 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04985812, the US trial registry maintained by the National Library of Medicine. NCT04985812 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.